Résumé
[64]Cu-pyruvaldehyde-bis [N[4]-methylthiosemicarbazone] [64]Cu-PTSM] is one of the most important copper radiopharmaceuticals used in clinical experiments. In this work, copper-64 [T[1/2]=12.33 h] production has been presented followed by the synthesis of the complexing agent, PTSM, and its structure was confirmed by common spectroscopic methods followed by radiolabeling with [64] Cu-actetate. The tracer was finally administered to fibrosarcoma-bearing rats and the biodistribution was determined in critical tissues as well as tumor. The final radiopharmaceutical solution underwent common quality control tests for animal injection a radiochemical purity >95% was determined. A significant tracer tumor uptake was observed 2 hours post injection. Tumonmuscle and tumonblood ratios were shown to be 8 and 6 respectively. [64]Cu-PTSM prepared in this report is a good candidate for tumor therapy as well as diagnosis for national use